|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
134 a.a.
|
 |
|
|
|
|
|
|
|
200 a.a.
|
 |
|
|
|
|
|
|
|
215 a.a.
|
 |
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Growth factor/growth factor receptor
|
 |
|
Title:
|
 |
Crystal structure of pro253arg apert mutant fgf receptor 2 (fgfr2) in complex with fgf2
|
|
Structure:
|
 |
Heparin-binding growth factor 2. Chain: a, b, c, d. Synonym: fgf2, hbgf-2, basic fibroblast growth factor, bfgf. Engineered: yes. Mutation: yes. Fibroblast growth factor receptor 2. Chain: e, f, g, h. Fragment: extracellular ligand binding domain consisting of ig-like domains ii (d2) and iii (d3), residues 147-366.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli bl21(de3). Expression_system_taxid: 469008.
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
2.30Å
|
R-factor:
|
0.237
|
R-free:
|
0.259
|
|
|
Authors:
|
 |
O.A.Ibrahimi,A.V.Eliseenkova,A.N.Plotnikov,D.M.Ornitz,M.Mohammadi
|
Key ref:
|
 |
O.A.Ibrahimi
et al.
(2001).
Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.
Proc Natl Acad Sci U S A,
98,
7182-7187.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
23-Apr-01
|
Release date:
|
09-May-01
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P09038
(FGF2_HUMAN) -
Fibroblast growth factor 2 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
288 a.a.
134 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
Chains E, F, G, H:
E.C.2.7.10.1
- receptor protein-tyrosine kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
|
 |
 |
 |
 |
 |
L-tyrosyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-tyrosyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
98:7182-7187
(2001)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.
|
|
O.A.Ibrahimi,
A.V.Eliseenkova,
A.N.Plotnikov,
K.Yu,
D.M.Ornitz,
M.Mohammadi.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Apert syndrome (AS) is characterized by craniosynostosis (premature fusion of
cranial sutures) and severe syndactyly of the hands and feet. Two activating
mutations, Ser-252 --> Trp and Pro-253 --> Arg, in fibroblast growth factor
receptor 2 (FGFR2) account for nearly all known cases of AS. To elucidate the
mechanism by which these substitutions cause AS, we determined the crystal
structures of these two FGFR2 mutants in complex with fibroblast growth factor 2
(FGF2). These structures demonstrate that both mutations introduce additional
interactions between FGFR2 and FGF2, thereby augmenting FGFR2-FGF2 affinity.
Moreover, based on these structures and sequence alignment of the FGF family, we
propose that the Pro-253 --> Arg mutation will indiscriminately increase the
affinity of FGFR2 toward any FGF. In contrast, the Ser-252 --> Trp mutation will
selectively enhance the affinity of FGFR2 toward a limited subset of FGFs. These
predictions are consistent with previous biochemical data describing the effects
of AS mutations on FGF binding. Alterations in FGFR2 ligand affinity and
specificity may allow inappropriate autocrine or paracrine activation of FGFR2.
Furthermore, the distinct gain-of-function interactions observed in each crystal
structure provide a model to explain the phenotypic variability among AS
patients.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Fig. 1. AS mutations do not affect the relative
disposition of D2 and D3 in FGFR2. C traces of
wild-type (green), mutant Ser252Trp (blue), and Pro253Arg (red)
FGFR2s are superimposed. The N and C termini are denoted by the
letters NT and CT. This figure was made by using programs
MOLSCRIPT (23) and RASTER3D (24). The C traces of
Ser252Trp and Pro253Arg mutant FGFR2s deviate by only 0.39
Å and 0.31 Å, respectively, from the C trace of
wild-type FGFR2.
|
 |
Figure 2.
Fig. 2. Gain-of-function interactions between the AS
mutant FGFR2s and FGF2. (A) Additional contacts between the N
terminus of FGF2 and the Ser252Trp mutant FGFR2. (B) Hydrogen
bonds between FGF2 and Arg-253 of the Pro253Arg mutant FGFR2. D2
and D3 of FGFR2 are shown in green and cyan, respectively. The
short linker that connects D2 and D3 is colored gray. FGF2 is
shown in orange. In addition, the FGF2 N-terminal region
(Phe^21-Pro-Pro-Gly24), which is ordered only in the Ser252Trp
mutant FGFR2-FGF2 structure, is colored purple. Oxygen atoms are
red, nitrogen atoms blue, and carbon atoms have the same
coloring as the molecules to which they belong. Dotted lines
represent hydrogen bonds. The hydrogen-bonding distances are
indicated. (Right) Views of whole structure in the exact
orientation as in the detailed views are shown, and the region
of interest is boxed. This figure was created by using the
programs MOLSCRIPT and RASTER3D.
|
 |
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.Nagata,
G.H.Nuckolls,
X.Wang,
L.Shum,
Y.Seki,
T.Kawase,
K.Takahashi,
K.Nonaka,
I.Takahashi,
A.A.Noman,
K.Suzuki,
and
H.C.Slavkin
(2011).
The primary site of the acrocephalic feature in Apert Syndrome is a dwarf cranial base with accelerated chondrocytic differentiation due to aberrant activation of the FGFR2 signaling.
|
| |
Bone,
48,
847-856.
|
 |
|
|
|
|
 |
W.H.Xu,
X.O.Shu,
J.Long,
W.Lu,
Q.Cai,
Y.Zheng,
Y.B.Xiang,
Q.Dai,
G.M.Zhao,
K.Gu,
P.P.Bao,
Y.T.Gao,
and
W.Zheng
(2011).
Relation of FGFR2 genetic polymorphisms to the association between oral contraceptive use and the risk of breast cancer in chinese women.
|
| |
Am J Epidemiol,
173,
923-931.
|
 |
|
|
|
|
 |
H.Miraoui,
J.Ringe,
T.Häupl,
and
P.J.Marie
(2010).
Increased EFG- and PDGFalpha-receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosis.
|
| |
Hum Mol Genet,
19,
1678-1689.
|
 |
|
|
|
|
 |
N.Martínez-Abadías,
C.Percival,
K.Aldridge,
C.A.Hill,
T.Ryan,
S.Sirivunnabood,
Y.Wang,
E.W.Jabs,
and
J.T.Richtsmeier
(2010).
Beyond the closed suture in apert syndrome mouse models: evidence of primary effects of FGFR2 signaling on facial shape at birth.
|
| |
Dev Dyn,
239,
3058-3071.
|
 |
|
|
|
|
 |
Y.Wang,
M.Sun,
V.L.Uhlhorn,
X.Zhou,
I.Peter,
N.Martinez-Abadias,
C.A.Hill,
C.J.Percival,
J.T.Richtsmeier,
D.L.Huso,
and
E.W.Jabs
(2010).
Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice.
|
| |
BMC Dev Biol,
10,
22.
|
 |
|
|
|
|
 |
A.Beenken,
and
M.Mohammadi
(2009).
The FGF family: biology, pathophysiology and therapy.
|
| |
Nat Rev Drug Discov,
8,
235-253.
|
 |
|
|
|
|
 |
B.C.Melnik
(2009).
Role of FGFR2-signaling in the pathogenesis of acne.
|
| |
Dermatoendocrinol,
1,
141-156.
|
 |
|
|
|
|
 |
E.G.Bochukova,
T.Roscioli,
D.J.Hedges,
I.B.Taylor,
D.Johnson,
D.J.David,
P.L.Deininger,
and
A.O.Wilkie
(2009).
Rare mutations of FGFR2 causing apert syndrome: identification of the first partial gene deletion, and an Alu element insertion from a new subfamily.
|
| |
Hum Mutat,
30,
204-211.
|
 |
|
|
|
|
 |
I.C.Welsh,
and
T.P.O'Brien
(2009).
Signaling integration in the rugae growth zone directs sequential SHH signaling center formation during the rostral outgrowth of the palate.
|
| |
Dev Biol,
336,
53-67.
|
 |
|
|
|
|
 |
M.K.Hajihosseini,
R.Duarte,
J.Pegrum,
A.Donjacour,
E.Lana-Elola,
D.P.Rice,
J.Sharpe,
and
C.Dickson
(2009).
Evidence that Fgf10 contributes to the skeletal and visceral defects of an apert syndrome mouse model.
|
| |
Dev Dyn,
238,
376-385.
|
 |
|
|
|
|
 |
S.R.Twigg,
C.Healy,
C.Babbs,
J.A.Sharpe,
W.G.Wood,
P.T.Sharpe,
G.M.Morriss-Kay,
and
A.O.Wilkie
(2009).
Skeletal analysis of the Fgfr3(P244R) mouse, a genetic model for the Muenke craniosynostosis syndrome.
|
| |
Dev Dyn,
238,
331-342.
|
 |
|
|
|
|
 |
S.R.Yoon,
J.Qin,
R.L.Glaser,
E.Wang Jabs,
N.S.Wexler,
R.Sokol,
N.Arnheim,
and
P.Calabrese
(2009).
The ups and downs of mutation frequencies during aging can account for the apert syndrome paternal age effect.
|
| |
PLoS Genet,
5,
e1000558.
|
 |
|
|
|
|
 |
U.M.Polanska,
L.Duchesne,
J.C.Harries,
D.G.Fernig,
and
T.K.Kinnunen
(2009).
N-Glycosylation regulates fibroblast growth factor receptor/EGL-15 activity in Caenorhabditis elegans in vivo.
|
| |
J Biol Chem,
284,
33030-33039.
|
 |
|
|
|
|
 |
B.Melnik,
and
G.Schmitz
(2008).
FGFR2 signaling and the pathogenesis of acne.
|
| |
J Dtsch Dermatol Ges,
6,
721-728.
|
 |
|
|
|
|
 |
M.L.Cunningham,
M.L.Seto,
C.Ratisoontorn,
C.L.Heike,
and
A.V.Hing
(2007).
Syndromic craniosynostosis: from history to hydrogen bonds.
|
| |
Orthod Craniofac Res,
10,
67-81.
|
 |
|
|
|
|
 |
P.M.Pollock,
M.G.Gartside,
L.C.Dejeza,
M.A.Powell,
M.A.Mallon,
H.Davies,
M.Mohammadi,
P.A.Futreal,
M.R.Stratton,
J.M.Trent,
and
P.J.Goodfellow
(2007).
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.
|
| |
Oncogene,
26,
7158-7162.
|
 |
|
|
|
|
 |
S.A.Newman,
and
R.Bhat
(2007).
Activator-inhibitor dynamics of vertebrate limb pattern formation.
|
| |
Birth Defects Res C Embryo Today,
81,
305-319.
|
 |
|
|
|
|
 |
J.L.Chung,
W.Wang,
and
P.E.Bourne
(2006).
Exploiting sequence and structure homologs to identify protein-protein binding sites.
|
| |
Proteins,
62,
630-640.
|
 |
|
|
|
|
 |
X.Zhang,
O.A.Ibrahimi,
S.K.Olsen,
H.Umemori,
M.Mohammadi,
and
D.M.Ornitz
(2006).
Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family.
|
| |
J Biol Chem,
281,
15694-15700.
|
 |
|
|
|
|
 |
A.Goriely,
G.A.McVean,
A.M.van Pelt,
A.W.O'Rourke,
S.A.Wall,
D.G.de Rooij,
and
A.O.Wilkie
(2005).
Gain-of-function amino acid substitutions drive positive selection of FGFR2 mutations in human spermatogonia.
|
| |
Proc Natl Acad Sci U S A,
102,
6051-6056.
|
 |
|
|
|
|
 |
A.O.Wilkie
(2005).
Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations.
|
| |
Cytokine Growth Factor Rev,
16,
187-203.
|
 |
|
|
|
|
 |
K.E.White,
J.M.Cabral,
S.I.Davis,
T.Fishburn,
W.E.Evans,
S.Ichikawa,
J.Fields,
X.Yu,
N.J.Shaw,
N.J.McLellan,
C.McKeown,
D.Fitzpatrick,
K.Yu,
D.M.Ornitz,
and
M.J.Econs
(2005).
Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation.
|
| |
Am J Hum Genet,
76,
361-367.
|
 |
|
|
|
|
 |
M.Ai,
S.L.Holmen,
W.Van Hul,
B.O.Williams,
and
M.L.Warman
(2005).
Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling.
|
| |
Mol Cell Biol,
25,
4946-4955.
|
 |
|
|
|
|
 |
M.Mohammadi,
S.K.Olsen,
and
O.A.Ibrahimi
(2005).
Structural basis for fibroblast growth factor receptor activation.
|
| |
Cytokine Growth Factor Rev,
16,
107-137.
|
 |
|
|
|
|
 |
M.Mohammadi,
S.K.Olsen,
and
R.Goetz
(2005).
A protein canyon in the FGF-FGF receptor dimer selects from an à la carte menu of heparan sulfate motifs.
|
| |
Curr Opin Struct Biol,
15,
506-516.
|
 |
|
|
|
|
 |
O.A.Ibrahimi,
B.K.Yeh,
A.V.Eliseenkova,
F.Zhang,
S.K.Olsen,
M.Igarashi,
S.A.Aaronson,
R.J.Linhardt,
and
M.Mohammadi
(2005).
Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization.
|
| |
Mol Cell Biol,
25,
671-684.
|
 |
|
|
|
|
 |
V.P.Eswarakumar,
I.Lax,
and
J.Schlessinger
(2005).
Cellular signaling by fibroblast growth factor receptors.
|
| |
Cytokine Growth Factor Rev,
16,
139-149.
|
 |
|
|
|
|
 |
B.K.Yeh,
M.Igarashi,
A.V.Eliseenkova,
A.N.Plotnikov,
I.Sher,
D.Ron,
S.A.Aaronson,
and
M.Mohammadi
(2003).
Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors.
|
| |
Proc Natl Acad Sci U S A,
100,
2266-2271.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
I.Nishimura,
R.L.Garrell,
M.Hedrick,
K.Iida,
S.Osher,
and
B.Wu
(2003).
Precursor tissue analogs as a tissue-engineering strategy.
|
| |
Tissue Eng,
9,
S77-S89.
|
 |
|
|
|
|
 |
J.J.Sanz-Ezquerro,
and
C.Tickle
(2003).
Fgf signaling controls the number of phalanges and tip formation in developing digits.
|
| |
Curr Biol,
13,
1830-1836.
|
 |
|
|
|
|
 |
L.Shum,
C.M.Coleman,
Y.Hatakeyama,
and
R.S.Tuan
(2003).
Morphogenesis and dysmorphogenesis of the appendicular skeleton.
|
| |
Birth Defects Res C Embryo Today,
69,
102-122.
|
 |
|
|
|
|
 |
R.L.Glaser,
K.W.Broman,
R.L.Schulman,
B.Eskenazi,
A.J.Wyrobek,
and
E.W.Jabs
(2003).
The paternal-age effect in Apert syndrome is due, in part, to the increased frequency of mutations in sperm.
|
| |
Am J Hum Genet,
73,
939-947.
|
 |
|
|
|
|
 |
A.O.Wilkie,
S.J.Patey,
S.H.Kan,
A.M.van den Ouweland,
and
B.C.Hamel
(2002).
FGFs, their receptors, and human limb malformations: clinical and molecular correlations.
|
| |
Am J Med Genet,
112,
266-278.
|
 |
|
|
|
|
 |
B.K.Yeh,
A.V.Eliseenkova,
A.N.Plotnikov,
D.Green,
J.Pinnell,
T.Polat,
A.Gritli-Linde,
R.J.Linhardt,
and
M.Mohammadi
(2002).
Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate.
|
| |
Mol Cell Biol,
22,
7184-7192.
|
 |
|
|
|
|
 |
L.Pellegrini
(2001).
Role of heparan sulfate in fibroblast growth factor signalling: a structural view.
|
| |
Curr Opin Struct Biol,
11,
629-634.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |
|